UW-Neurocrine Biosciences
HEOR FELLOWSHIP PROGRAM
2022-2024
About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 30 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. **Headquartered in San Diego**, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. *in collaboration with AbbVie

About UW School of Pharmacy-CHOICE Institute

The University of Washington is a national leader in health sciences education and has been consistently listed in U.S. News and World Report as one of the top ten such institutions for its graduate programs. It fosters a highly collegial atmosphere between disciplines, creating a particularly attractive environment for such partnerships between the public and private sectors as the UW and Neurocrine Fellowship. The fellowship will offer a masters from the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute housed within the University of Washington School of Pharmacy.

The CHOICE Institute has helped the University of Washington become a nationally recognized center for pharmacoepidemiology, pharmacoeconomics, comparative effectiveness research, and pharmaceutical outcomes research.
## Products and Pipeline

### COMMERICALLY AVAILABLE

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>INDICATION</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>valbenazine</strong></td>
<td>Tardive Dyskinesia (Japan)</td>
<td><strong>FILED MARKETING AUTHORIZATION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>valbenazine</strong></td>
<td>Chorea in Huntington Disease</td>
<td></td>
<td>REGISTRATIONAL</td>
<td></td>
</tr>
<tr>
<td><strong>valbenazine</strong></td>
<td>Dyskinesia Due to Cerebral Palsy</td>
<td></td>
<td>REGISTRATIONAL</td>
<td></td>
</tr>
<tr>
<td><strong>NBI-827104</strong></td>
<td>Rare Pediatric Epilepsy: CSWS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NBI-827104</strong></td>
<td>Essential Tremor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NBI-921352</strong></td>
<td>Rare Pediatric Epilepsy: SCN8A-DEE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NBI-921352</strong></td>
<td>Focal-Onset Seizures in Adults</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>crinecerfont</strong></td>
<td>Congenital Adrenal Hyperplasia (Adult)</td>
<td></td>
<td>REGISTRATIONAL</td>
<td></td>
</tr>
<tr>
<td><strong>crinecerfont</strong></td>
<td>Congenital Adrenal Hyperplasia (Pediatric)</td>
<td></td>
<td>REGISTRATIONAL</td>
<td></td>
</tr>
<tr>
<td><strong>valbenazine</strong></td>
<td>Adjunctive Treatment of Schizophrenia</td>
<td></td>
<td>REGISTRATIONAL</td>
<td></td>
</tr>
<tr>
<td><strong>luvadaxistat</strong> (NBI-1065844)</td>
<td>Cognitive Impairment Associated with Schizophrenia (CIAS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NBI-1065845</strong></td>
<td>Inadequate Response to Treatment in Major Depressive Disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NBI-1065846</strong></td>
<td>Anhedonia in Depression</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CSWS = Epileptic Encephalopathy with Continuous Spikes and Waves During Sleep
Neurocrine Biosciences has global rights, unless otherwise noted.
*Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia.* ‡Under license from Bial. †Abbvie has global commercialization rights.
Dear Candidates,

As you consider the next chapter in your professional career, we would like to thank you for your interest in exploring our UW-Neurocrine Biosciences Industry Fellowships in Health Economics & Outcomes Research (HEOR).

As founders and directors of the fellowship program here at Neurocrine, we are committed to providing experiences that will help shape future leaders and innovators in the field of HEOR. To guide and prepare our fellows for a career in HEOR, our program combines a world class HEOR education at UW-CHOICE Institute with opportunities for projects in Neurocrine across the development lifecycle.

Our fellow will become part of our HEOR team. At Neurocrine, HEOR conducts research to inform decision making at many stages in the product life cycle from research and development to pricing, market access, strategic planning and lifecycle management. The fellow will contribute to meaningful projects designed to advance patient care and support Neurocrine’s pipeline agents and marketed products.

We prioritize teamwork, education and trust. We are innovative, agile and passionate about using patient centric, real-world evidence to improve patient lives. Our fellow will be a contributing and valued team member within HEOR and the greater Neurocrine family.

We wish you the best of luck as you explore the different fellowships available to you, and we strongly encourage you to consider our HEOR Fellowship. On behalf of Neurocrine, we look forward to your application to our program.

Sincerely,

Mallory Farrar, PharmD  Michael Serbin, PharmD, MS
Fellowship Lead  Fellowship Mentor
Manager, HEOR  Director, HEOR

At Neurocrine Biosciences we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.
Mallory Farrar is the HEOR lead in congenital adrenal hyperplasia (CAH) within Medical Affairs. In this role she leads the strategic development and execution of research to support the value message for the CAH program. Her projects range from systematic literature reviews, economic models, patient preference studies and registry analyses. In addition, she is the lead preceptor for our HEOR summer intern and PharmD rotational students.

Before joining Neurocrine, Mallory completed her post-doc fellowship at Eli Lilly and Company in their Global Patient Outcomes and Real World Evidence (GPORWE) group within their Biomedicines department. She supported PRO work, patient preference studies and published a systematic literature review on migraine. She also co-taught an introduction to industry course for PharmD students at the University of Butler.

Michael Serbin is a director on the HEOR team and Neurocrine’s HEOR program lead for Parkinson’s Disease and essential tremor. Michael received his PharmD and MS in HEOR from the University of Washington. Michael is involved in many HEOR projects and real-world evidence studies across Neurocrine’s expanding number of programs.

Before joining Neurocrine, Michael completed an HEOR post-doc fellowship with UW-CHOICE and Allergan PLC. Michael supported the eye-care portfolio contributing to published works in glaucoma and neovascular age-related macular degeneration.

Rahul joined NBI in 2019, and has worked in the pharmaceutical, biotech, and medical device sectors of the healthcare industry, as well as with contract research organizations over the past 3 decades. During this time Rahul has developed a keen understanding of Health Economics and Outcomes Research (HEOR). In particular, its intersection with Clinical Development, patient centric research, economic value development, reimbursement and market access.

Rahul also holds an adjunct associate professorship with the University of Texas Health San Antonio, the largest health sciences university in South Texas. He is also on the editorial board of an applied statistical journal, RAS Oncology and Therapy, and has been a peer reviewer for several academic journals as well as engaged with ISPOR, ISPE, and ISOQOL.

University of Washington Fellowship Advisors

Sean D. Sullivan, BScPharm, PhD
Professor and Dean
UW School of Pharmacy

Ryan Hansen, PharmD, PhD
Associate Professor
Department of Pharmacy,
The CHOICE Institute
UW Fellowship Director
Health Economics & Outcomes Research Fellowship

The two-year HEOR Fellowship is designed to provide technical training paired with on the job pharmaceutical industry experience. The fellow will gain exposure to a variety of HEOR related activities, such as economic modeling, epidemiology studies, burden of disease/illness research, and PRO development. The HEOR/medical affairs team has a strong reputation in the industry for HEOR research and publications, field medical education and real-world evidence generation.

Upon completion of the program, the fellow will have an academic foundation in HEOR paired with hands on training in a variety of HEOR activities, in order to lead a successful career in the life sciences industry, such as biotech, government payers, pharma, and device manufacturers.

Fellowship Structure

- **Year 1:**
  - University of Washington School of Pharmacy, Seattle WA
  - Earn Masters (MS) in Health Economics and Outcomes Research
  - Course work focuses on modeling, epidemiology, medical biometry along with a longitudinal project

- **Year 2:**
  - Neurocrine Biosciences, San Diego CA
  - Implement learnings from master’s program to assist in HEOR evidence generation and value messaging strategy for products throughout the development lifecycle

  - The HEOR fellow will join a class of fellows at Neurocrine from Medical Communications, Field Medical-Medical Science Liaison, Publications and Regulatory

Fellowship Objectives

- Support ongoing HEOR deliverables across the product lifecycle in areas of health economics, market access, payer engagement, burden of illness, clinical outcome assessments & PROs, and epidemiologic studies
- Collaborate with cross functional teams and other industry fellows
- Complete required graduate coursework at the University of Washington School of Pharmacy and earn MS
- Become an integral and impactful member of the HEOR team and Neurocrine in our mission to relieve patient suffering and enhance lives
Application Requirements

- PharmD
- Previous experience in health economics and outcomes research preferred
- Good oral and written communication skills, ethics, professionalism, leadership and an interest in the biopharmaceutical industry
- CV, transcripts, 3 letters of recommendation and statement of purpose

Application Process Timeline

- Eligibility: Degree in Pharmacy by July 1, 2022
- Application Deadline: Friday, October 29, 2021
- Interview Notification: Wednesday, November 3, 2021
- Interviews: Week of November 8, 2021
- Offer Notification: Friday, November 12, 2021 — decisions requested by Nov 15 and 16
- Program Start Date: July 1, 2022

How to Apply

Please apply directly through the University of Washington Graduate School Application
- Start your Graduate School Application
- Create a new application:
- Select the following for each category:
  - Application type: Graduate
  - Program: Pharmacy – Health Economics & Outcomes Research (MS)
  - Quarter and Year: Fall 2022
  - Areas of Interest: Neurocrine Fellowship Program
- Complete all steps:
  - Report prior schools, submit transcripts, submit CV, designate 3 recommenders, statement of purpose
  - Verify, Pay, and Submit Application no later than October 29, 2021

Point of Contact

For more information, please contact:

Marina Gano, M.Ed.
Graduate Program &
Operations Manager
The CHOICE Institute,
Department of Pharmacy
206-616-1383
uwssopchoice@uw.edu

Ryan Hansen, PharmD, PhD
Associate Professor &
Director of Industry Fellowships
The CHOICE Institute,
Department of Pharmacy
rhansen@uw.edu

Mallory Farrar, PharmD
HEOR Manager and
Fellowship Lead
Neurocrine Biosciences, Inc.
mfarrar@neurocrine.com

Marina Gano, M.Ed.
Graduate Program &
Operations Manager
The CHOICE Institute,
Department of Pharmacy
206-616-1383
uwssopchoice@uw.edu

Ryan Hansen, PharmD, PhD
Associate Professor &
Director of Industry Fellowships
The CHOICE Institute,
Department of Pharmacy
rhansen@uw.edu

Mallory Farrar, PharmD
HEOR Manager and
Fellowship Lead
Neurocrine Biosciences, Inc.
mfarrar@neurocrine.com